Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Åsa Ericsson"'
Publikováno v:
PLoS ONE, Vol 13, Iss 2, p e0191953 (2018)
We assessed the cost-effectiveness of the glucagon-like peptide 1 receptor agonists liraglutide 1.8 mg and lixisenatide 20 μg (both added to basal insulin) in patients with type 2 diabetes (T2D) in Sweden.The Swedish Institute for Health Economics c
Externí odkaz:
https://doaj.org/article/c5a5bb8534e24bada06f77761d908fce
Autor:
Nikolaos Kotsopoulos, Mark P. Connolly, Michael Willis, Andreas Nilsson, Åsa Ericsson, James Baker‐Knight
Publikováno v:
Diabetes obesity & metabolism, 24(6), 1038-1046. Wiley
Aim To estimate the fiscal burden for taxpayers in Sweden associated with type 2 diabetes (T2D) attributed to diabetes-related complications in patients failing to meet HbA1c targets. Material and Methods We developed a public economic framework to a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ce6b7f23b8ab8676eab74a210b6bc56
https://doi.org/10.1111/dom.14667
https://doi.org/10.1111/dom.14667
Autor:
Barnaby Hunt, Jonas B. Møller, Jens Gundgaard, Åsa Ericsson, Johan Jendle, William J. Valentine
Publikováno v:
Diabetes Therapy
Introduction Real-world evidence has demonstrated improved glycemic control and insulin management following introduction of smart insulin pens in a Swedish type 1 diabetes (T1D) population. To understand the implications for healthcare costs and exp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56b1dc0785950b2541a4bdf7e97f17a7
https://doi.org/10.1007/s13300-020-00980-1
https://doi.org/10.1007/s13300-020-00980-1
Autor:
Åsa Ericsson, Johan Jendle, Emelie Andersson, Nino Hallén, Katarina Steen Carlsson, Peter Lindgren, Desirée Thielke, Sofie Persson
Publikováno v:
Diabetologia
Aims/hypothesis The risk of complications and medical consequences of type 2 diabetes are well known. Hospital costs have been identified as a key driver of total costs in studies of the economic burden of type 2 diabetes. Less evidence has been gene
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce9723e06511b7ac83bd9957314218c5
https://doi.org/10.1007/s00125-020-05277-3
https://doi.org/10.1007/s00125-020-05277-3
Autor:
Jens Gundgaard, Ann Charlotte Mårdby, Barnaby Hunt, Åsa Ericsson, Johan Jendle, Joao Diogo Da Rocha Fernandes, Bertil Ekman, Samuel J. P. Malkin, Maria Thunander, Stefan Sjöberg
Publikováno v:
Journal of Medical Economics. 23:1311-1320
Background and Aims: The ReFLeCT study demonstrated that switching to insulin degludec from other basal insulins was associated with reductions in glycated hemoglobin and hypoglycemic events in type 1 (T1D) and type 2 diabetes (T2D), and reductions i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c8d4f71ccbf7026d4f815f0519f0c14
https://doi.org/10.1080/13696998.2020.1805454
https://doi.org/10.1080/13696998.2020.1805454
Publikováno v:
PharmacoEconomics - open. 6(3)
The aim of this study was to assess the cost effectiveness of oral semaglutide versus other oral glucose-lowering drugs for the management of type 2 diabetes (T2D) in Sweden.The Swedish Institute for Health Economics Diabetes Cohort Model was used to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1aa6c9189c3babd2e2441ef4a4a62de2
https://pubmed.ncbi.nlm.nih.gov/35064550
https://pubmed.ncbi.nlm.nih.gov/35064550
Autor:
Sarah N. Ali, Barnaby Hunt, Åsa Ericsson, Klaus Kallenbach, Samuel J. P. Malkin, Brian Bekker Hansen, William J. Valentine, Tam Dang-Tan
Publikováno v:
Advances in Therapy
Introduction Oral semaglutide is the first orally administered glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes, and has been evaluated in the PIONEER clinical trial program. These trials assessed the proportions of patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::275bcef2074d3bb9d3f553869f6cae94
http://europepmc.org/articles/PMC6860465
http://europepmc.org/articles/PMC6860465
Autor:
Åsa Ericsson, Ann-Marie Svensson, Samuel J. P. Malkin, William J. Valentine, Soffia Gudbjörnsdottir, Nils Ekström, Stefan Franzén, Rebecka Bertilsson, Margareta Hellgren
Publikováno v:
Diabetes, Obesity & Metabolism
Aim To evaluate the economic and clinical burden associated with poor glycaemic control in Sweden, in people with type 2 diabetes (T2D) initiating first‐line glucose‐lowering therapy. Materials and Methods Population data were obtained from Swedi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d90e5b24c29c44a0969c772df8add590
https://pubmed.ncbi.nlm.nih.gov/33729661
https://pubmed.ncbi.nlm.nih.gov/33729661
Autor:
Peter Lindgren, Johan Jendle, Desirée Thielke, Katarina Steen Carlsson, Emelie Andersson, Sofie Persson, Åsa Ericsson, Nino Hallén
Publikováno v:
Diabetes. 69
Background: The prevalence of type 2 diabetes (T2D) has increased rapidly over the last decades. The risks of complications and the medical consequences are well known, where hospital costs have been identified as a key driver of total costs. Less ev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b4035604148a78f2970a9fd63f61e599
https://doi.org/10.2337/db20-1165-p
https://doi.org/10.2337/db20-1165-p
Publikováno v:
Diabetes Therapy
Introduction Sweden has amongst the highest incidence rates of type 1 diabetes (T1D) in Europe. The high incidence and chronic nature of T1D result in high prevalence and economic burden. Improving glycemic control reduces the incidence of microvascu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a9ebbcef172caabeffb66aa99708025
https://doi.org/10.1007/s13300-017-0344-6
https://doi.org/10.1007/s13300-017-0344-6